Tharimmune, Inc. (THAR)

NASDAQ: THAR · IEX Real-Time Price · USD

3.240

+0.120 (3.85%)

At close: Jul 26, 2024, 3:59 PM

3.020

-0.220 (-6.79%)

After-hours: Jul 26, 2024, 5:31 PM EDT

Tharimmune Employees

As of December 31, 2023, Tharimmune had 3 total employees, including 2 full-time and 1 part-time employees. The number of employees increased by 1 or 50.00% compared to the previous year.

Employees

3

Change (1Y)

1

Growth (1Y)

50.00%

Revenue / Employee

n/a

Profits / Employee

-$2,962,305

Market Cap

3.55M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2023	3	1	50.00%
Dec 31, 2022	2	0	-
Dec 31, 2021	2	-	-

Related Stocks

Company Name	Employees
Venus Concept	304
Fresh2 Group	75
Avinger	72
iSpecimen	53
Sintx Technologies	43
Onconetix	12
Bio-Path Holdings	10
ZyVersa Therapeutics	7

Employee Rankings

THAR News

4 days ago - Tharimmune Appoints Prof. David Jones of Newcastle University to its Scientific Advisory Board - Accesswire
9 days ago - Tharimmune Appoints Global Business Executive David H. Clarke as Key Strategic Advisor - Accesswire
6 weeks ago - Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis - Accesswire
3 months ago - Tharimmune To Participate in Two Upcoming Investor Conferences in May - Accesswire
3 months ago - Tharimmune Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates (ADCs) - Accesswire
3 months ago - Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics - Accesswire
5 months ago - Tharimmune to Present at the Emerging Growth Conference on March 7, 2024 - Accesswire
5 months ago - Tharimmune Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic Candidate - Accesswire